ALLO
$2.07-0.15 (-6.76%)
Allogene Therapeutics, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UC...
Recent News
Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is one of the 10 most active penny stocks to buy. On March 13, 2026, Biren Amin, an analyst at Piper Sandler, maintained an “Overweight” rating on Allogene Therapeutics, Inc. (NASDAQ:ALLO) and increased the price target of the stock from $7 to $8. Amin noted increased anticipation surrounding the company’s upcoming […]
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4
ALLO posts a narrower Q4 loss than expected, cuts expenses and advances key CAR-T studies, with cash projected to fund operations into 2028.
Allogene Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Allogene Therapeutics, Inc.'s Q4 2025 earnings call
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlights: Financial Stability and ...
Allogene Therapeutics Inc (ALLO) extends its cash runway into 2028 while focusing on pivotal clinical milestones and innovative treatment strategies.
Allogene Therapeutics Q4 Earnings Call Highlights
Allogene Therapeutics (NASDAQ:ALLO) used its fourth-quarter 2025 conference call to outline what management described as a “defining year” ahead, with multiple clinical catalysts expected in 2026 and an updated financial outlook extending its cash runway into the first quarter of 2028. 2026 focus: